In pharmacokinetic and clinical studies of once daily 500 mg levofloxacin (LVFX) in adults with acute pharyngotonsillitis, we assessed disease severity and LVFX efficacy using scoring based on local findings and clinical symptoms.
The LVFX tissue concentration of 2.58 to 4.12 hours after single 500 mg administration was 7.791±1.686 μg/g (mean±SD) in the palatine tonsil, with a tissue/plasma concentration ratio of 1.66±0.20. The clinical efficacy (test of cure) was 95.0% (19/20). Bacteriological eradication was 100% (7/7). Adverse reactions, all mild to moderate, occurred in 28.6% (6/21). Side effects, but no serious or clinically significant event, occurred in 4.8% (1/21).
In conclusion, LVFX once daily 500 mg p.o. entered well into palatine tonsil tissue and appears useful in treating acute pharyngotonsillitis. Data confirmed that scoring was very useful in deciding appropriate acute pharyngotonsillitis treatment.
